Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.40 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29722045 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29282662 | 0.87 | ALDH1A1 (0.38) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17504828 | 0.86 | ALDH1A1 (0.40) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30515386 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP1A2CYP2C19TSHR | |
| SCHEMBL3061406 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP1A2CYP2C19TSHR | |
| SCHEMBL29838652 | 0.80 | AAK1 (0.48) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3060388 | 0.79 | GPR35 (0.41) | ALDH1A1MAPTCYP1A2CYP2C9TSHR | |
| SCHEMBL3059793 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MAPTTSHRTDP1CYP3A4 | |
| SCHEMBL19433305 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2340152 | 0.77 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-12258354-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4452984-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Molecure S.A. (PL) | 2024-10-30 | — | — | EP | disclosed |
| EP-3749669-B3 | AHR MODULATORS | IDEAYA BIOSCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| CN-118027034-A | Purine derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-111683950-B | AhR modulators | 伊迪亚生物科学有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117396485-A | PARP7 inhibitors | 轩竹生物科技股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4219495-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| EP-2521727-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | Laboratoires Fournier S.A. (FR) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011083278-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | LABORATOIRES FOURNIER SA (FR) | 2011-07-14 | — | — | WO | disclosed |
| US-7910592-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | ALDH1A1 3603/4885MAPT 2376/4885CYP1A2 886/4885 |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | NCOR1, NCOR2, NR0B1 | ALDH1A1 1066/4885MAPT 3895/4885CYP1A2 998/4885 |
| US-12258354-B2 | AhR modulators | AHR, ARNT, RORB | ALDH1A1 579/4885MAPT 4102/4885CYP1A2 39/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | ALDH1A1 3140/4885MAPT 32/4885CYP1A2 398/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | ALDH1A1 2210/4885MAPT 1555/4885CYP1A2 3846/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | ALDH1A1 1388/4885MAPT 614/4885CYP1A2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.